DrugDashboards

Glecaprevir CV Pibrentasvir

Glecaprevir CV Pibrentasvir · PIBRENTASVIR 40 mg/1; GLECAPREVIR 100 mg/1 · Tablet, Film Coated · AbbVie Deutschland GmbH & Co Kg

NDC 12613-2625-09 · 10300 TABLET, FILM COATED in 1 DRUM · DRUG FOR FURTHER PROCESSING · View full market →

Bulk ingredient — not a finished product

This NDC is a raw material (drug for further processing) sold to drug manufacturers or compounders, not a product pharmacies dispense. Retail pricing, TE codes, fragility scores, and shortage reports don't apply to bulk listings — those attach to finished products made from this ingredient.

Medicare Part D

This is a bulk ingredient, not a dispensable product — it is a raw material sold to manufacturers and compounders, so no plan prices it.

How Part D pricing works →

NADAC price per unit

No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.

Supply fragility

Not scored — fragility is computed for NADAC-priced NDCs.

Regulatory

Application
TE code
Approval date
Patents / exclusivity

Shortage history

No FDA shortage reports for this drug or its presentations.

Recalls (this NDC)

No enforcement reports list this package NDC.

Manufacturers of Glecaprevir CV Pibrentasvir (Tablet, Film Coated)

LabelerStrengthFirst seenLast seen
AbbVie Deutschland GmbH & Co KgPIBRENTASVIR 40 mg/1; GLECAPREVIR 100 mg/1Aug 20, 2026Sep 3, 2026
AbbVie Deutschland GmbH & Co KgPIBRENTASVIR 100 mg/1; GLECAPREVIR 40 mg/1Jul 22, 2026Aug 19, 2026
AbbVie Deutschland GmbH & Co KgGLECAPREVIR 100 mg/1; PIBRENTASVIR 40 mg/1Jul 15, 2026Jul 15, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Glecaprevir CV Pibrentasvir — NDC 12613-2625-09," retrieved September 3, 2026, https://drugdashboards.com/drug/12613262509.

Free to cite with attribution — see how the data is put together.